De novo accelerated phase of chronic myeloid leukemia should be
recognized even in the era of tyrosine kinase inhibitors

J 2024

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

HORŇÁK, Tomáš, Jiří MAYER, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Anežka KVETKOVÁ et. al.

Basic information

Original name

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

Authors

HORŇÁK, Tomáš (703 Slovakia, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Petra ČIČÁTKOVÁ (203 Czech Republic, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Anežka KVETKOVÁ (703 Slovakia, belonging to the institution), Hana KLAMOVA (203 Czech Republic), Edgar FABER (203 Czech Republic), Petra BELOHLAVKOVA (203 Czech Republic), Michal KARAS (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Eduard CMUNT (203 Czech Republic), Olga CERNA (203 Czech Republic), Dana SRBOVA (203 Czech Republic), Hana ZIZKOVA (203 Czech Republic), Lucia VRABLOVA (203 Czech Republic), Ivana SKOUMALOVA (203 Czech Republic), Jaroslava VOGLOVA (203 Czech Republic), Tereza JURKOVA (203 Czech Republic), Marika CHRAPAVA (203 Czech Republic), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Marie JAROŠOVÁ (203 Czech Republic, belonging to the institution), Katerina MACHOVA POLAKOVA (203 Czech Republic), Tomas PAPAJIK (203 Czech Republic), Pavel ZAK (203 Czech Republic), Pavel JINDRA (203 Czech Republic) and Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution)

Edition

American Journal of Hematology, Hoboken, Wiley-Blackwell, 2024, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 12.800 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ajh.27229

UT WoS

001157508900001

Keywords in English

chronic myeloid leukemia; tyrosine kinase inhibitors

Abstract

V originále

Chronic myeloid leukemia (CML) has been described as a triphasic disease for several decades. Before the introduction of tyrosine kinase inhibitors (TKIs), the course of the disease ran from the chronic phase to the accelerated phase (AP), noticeable by changes in the complete blood count, with left shift, additional cytogenetic changes, etc. The original definition of AP was proposed by the MD Anderson group. Disease then progressed to blast crisis (BC), with a portion of blast cells in the blood or bone marrow comparable to acute leukemias. Most patients with CML experienced all three phases, with those progressing to AP and BC having a poor prognosis. This has been recognized in the most renowned CML classifications and guidelines, including the WHO and ICC classifications, and the ELN and NCCN guidelines. The criteria for AP and BC were defined, although some differences existed among the classifications (e.g., blast percentage thresholds and certain cytogenetic abnormalities). After the TKI revolution in CML treatment, the situation completely changed. Patients receiving TKIs rarely progress to advanced phases; in some cases, the progression to blast crisis seems to be rapid, often without signs of AP. In light of this fact, the latest WHO 2022 classification deemed AP less relevant and suggested its omission. This step has sparked numerous discussions. Notably, there are two distinctive groups of patients with AP: those newly diagnosed with AP without any previous CML treatment and those who progressed from previously treated CP, with the latter being more common and having worse survival Here, we present the results of our nationwide CML database analysis, focusing on the prognosis of patients fulfilling the criteria of AP CML at the time of their diagnosis.

Links

LX22NPO5102, research and development project

Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)

Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES

MUNI/A/1558/2023, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit XI

Investor: Masaryk University

Citovat

HORŇÁK, Tomáš, Jiří MAYER, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Anežka KVETKOVÁ, Hana KLAMOVA, Edgar FABER, Petra BELOHLAVKOVA, Michal KARAS, Lukas STEJSKAL, Eduard CMUNT, Olga CERNA, Dana SRBOVA, Hana ZIZKOVA, Lucia VRABLOVA, Ivana SKOUMALOVA, Jaroslava VOGLOVA, Tereza JURKOVA, Marika CHRAPAVA, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marie JAROŠOVÁ, Katerina MACHOVA POLAKOVA, Tomas PAPAJIK, Pavel ZAK, Pavel JINDRA and Daniela ŽÁČKOVÁ. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American Journal of Hematology. Hoboken: Wiley-Blackwell, 2024, vol. 99, No 4, p. 763-766. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.27229.

@article{2376680,
   author = {Horňák, Tomáš and Mayer, Jiří and Čičátková, Petra and Semerád, Lukáš and Kvetková, Anežka and Klamova, Hana and Faber, Edgar and Belohlavkova, Petra and Karas, Michal and Stejskal, Lukas and Cmunt, Eduard and Cerna, Olga and Srbova, Dana and Zizkova, Hana and Vrablova, Lucia and Skoumalova, Ivana and Voglova, Jaroslava and Jurkova, Tereza and Chrapava, Marika and Jurček, Tomáš and Ježíšková, Ivana and Jarošová, Marie and Machova Polakova, Katerina and Papajik, Tomas and Zak, Pavel and Jindra, Pavel and Žáčková, Daniela},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1002/ajh.27229},
   keywords = {chronic myeloid leukemia; tyrosine kinase inhibitors},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/ajh.27229},
   volume = {99},
   year = {2024}
}

TY  - JOUR
ID  - 2376680
AU  - Horňák, Tomáš - Mayer, Jiří - Čičátková, Petra - Semerád, Lukáš - Kvetková, Anežka - Klamova, Hana - Faber, Edgar - Belohlavkova, Petra - Karas, Michal - Stejskal, Lukas - Cmunt, Eduard - Cerna, Olga - Srbova, Dana - Zizkova, Hana - Vrablova, Lucia - Skoumalova, Ivana - Voglova, Jaroslava - Jurkova, Tereza - Chrapava, Marika - Jurček, Tomáš - Ježíšková, Ivana - Jarošová, Marie - Machova Polakova, Katerina - Papajik, Tomas - Zak, Pavel - Jindra, Pavel - Žáčková, Daniela
PY  - 2024
TI  - De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
JF  - American Journal of Hematology
VL  - 99
IS  - 4
SP  - 763-766
EP  - 763-766
PB  - Wiley-Blackwell
SN  - 03618609
KW  - chronic myeloid leukemia
KW  - tyrosine kinase inhibitors
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ajh.27229
N2  - Chronic myeloid leukemia (CML) has been described as a triphasic disease for several decades. Before the introduction of tyrosine kinase inhibitors (TKIs), the course of the disease ran from the chronic phase to the accelerated phase (AP), noticeable by changes in the complete blood count, with left shift, additional cytogenetic changes, etc. The original definition of AP was proposed by the MD Anderson group. Disease then progressed to blast crisis (BC), with a portion of blast cells in the blood or bone marrow comparable to acute leukemias. Most patients with CML experienced all three phases, with those progressing to AP and BC having a poor prognosis. This has been recognized in the most renowned CML classifications and guidelines, including the WHO and ICC classifications, and the ELN and NCCN guidelines. The criteria for AP and BC were defined, although some differences existed among the classifications (e.g., blast percentage thresholds and certain cytogenetic abnormalities). After the TKI revolution in CML treatment, the situation completely changed. Patients receiving TKIs rarely progress to advanced phases; in some cases, the progression to blast crisis seems to be rapid, often without signs of AP. In light of this fact, the latest WHO 2022 classification deemed AP less relevant and suggested its omission. This step has sparked numerous discussions. Notably, there are two distinctive groups of patients with AP: those newly diagnosed with AP without any previous CML treatment and those who progressed from previously treated CP, with the latter being more common and having worse survival Here, we present the results of our nationwide CML database analysis, focusing on the prognosis of patients fulfilling the criteria of AP CML at the time of their diagnosis.
ER  -

HORŇÁK, Tomáš, Jiří MAYER, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Anežka KVETKOVÁ, Hana KLAMOVA, Edgar FABER, Petra BELOHLAVKOVA, Michal KARAS, Lukas STEJSKAL, Eduard CMUNT, Olga CERNA, Dana SRBOVA, Hana ZIZKOVA, Lucia VRABLOVA, Ivana SKOUMALOVA, Jaroslava VOGLOVA, Tereza JURKOVA, Marika CHRAPAVA, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marie JAROŠOVÁ, Katerina MACHOVA POLAKOVA, Tomas PAPAJIK, Pavel ZAK, Pavel JINDRA and Daniela ŽÁČKOVÁ. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. \textit{American Journal of Hematology}. Hoboken: Wiley-Blackwell, 2024, vol.~99, No~4, p.~763-766. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.27229.

Detailed Information on Publication Record